


PHARMACEUTICAL 2017

MusclePharm Corp Rank 98 of 313







PHARMACEUTICAL 2017



MusclePharm Corp Rank 98 of 313

The relative strengths and weaknesses of MusclePharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MusclePharm Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1,348% points. The greatest weakness of MusclePharm Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 926% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 363% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	28,794
Cost of Goods Sold	88,026
Intangible Assets	1,638
Liabilities, Current	38,436
Liabilities, Non-Current	0
Other Assets	421
Other Compr. Net Income	10
Other Expenses	35,639
Other Liabilities	540
Other Net Income	5,499
Property and Equipment	3,243
Research and Development	1,869
Revenues	132,499
Selling, General and Administrative Expense	15,941

Output Variable	Value in 1000 USD
Assets	34,096
Liabilities	38,976
Expenses	141,475
Stockholders Equity	-4,880
Net Income	-3,477
Comprehensive Net Income	-3,472
Economic Capital Ratio	-53%